Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Ensituximab Shows Modest Single-Agent Activity in CRC, Combinations to Be Explored

June 8th 2020

The novel chimeric monoclonal antibody ensituximab demonstrated modest clinical activity and was found to be well tolerated in patients with heavily pretreated, refractory colorectal cancer.

Dr. Nelson on the Future Utility of ctDNA in CRC

June 5th 2020

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Dr. Armaghany on the Utility of ctDNA in CRC

June 4th 2020

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Encorafenib Plus Cetuximab Approved in Europe for BRAF V600E-Mutant mCRC

June 3rd 2020

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

Continued OS Advantage With Encorafenib/Cetuximab Cements Role in BRAF+ mCRC

June 3rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Bekaii-Saab Highlights Targeted Therapy Advances in CRC

June 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors

May 31st 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E-Mutant CRC

May 30th 2020

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC

May 29th 2020

Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.

FDA Grants Onvansertib Fast Track Designation in KRAS+ mCRC

May 28th 2020

The FDA has granted Fast Track designation to onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

Dr. Mizrahi on Targeting Treatment in Metastatic Colorectal Cancer

May 28th 2020

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Dr. Le on Research Needed to Address Unmet Needs in mCRC

May 27th 2020

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Dr. Raghav on the Utility of ctDNA in CRC

May 27th 2020

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 22nd 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Multimodal Blood Test Successfully Screens for Advanced CRC, Adenomas

May 8th 2020

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Onvansertib Regimen Shows Early Promise in KRAS-Mutant mCRC

May 7th 2020

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.